India caps trade margins on 42 anti-cancer medicines
India has put a cap on the trade margin of 42 selected non-scheduled anti-cancer medicines, including ribociclib, which is used to treat breast.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
India has put a cap on the trade margin of 42 selected non-scheduled anti-cancer medicines, including ribociclib, which is used to treat breast.
The WHO has issued a medical product alert on a contaminated cancer and autoimmune disease treatment drug made by Hyderabad, India-based Celon Laboratories,.
A ransomware group has breached the information security network of India's Sun Pharmaceuticals unit, and there is a possibility that "file systems, business and personal.
The Indian government and the World Bank signed two agreements to support and enhance the development of the health sector in the south.
India's WiproLab45 unveiled its Decentralized Identity and Credential Exchange (DICE) ID to put the user in control of their medical data, approval to.
India-based Global Pharma Healthcare voluntarily recalled all lots of its artificial tears lubricant eye drops after the USFDA reported possible contamination.
Max Healthcare, one of India’s largest private hospital chains, reported a 7% rise in profit after tax, on revenue of INR 15.6 billion,.
Stelis Biopharma, a division of India’s Strides Pharma Science, will become a full-fledged contract development and manufacturing firm and may list “near-term.
Glenmark Pharmaceuticals, an Indian global drug maker with a focus on dermatology, respiratory and oncology areas, forecasts lifting of China's COVID-19 curbs may.
The Indian pharmaceutical market is estimated to be worth $130 billion by 2030 from an estimated US$ 41 billion in 2021, the Economic.